Trafalgar International (GCAN) Net Income towards Common Stockholders (2017 - 2026)
Trafalgar International (GCAN) posted Net Income towards Common Stockholders of -$33376.0 for Q1 2026, down 109.88% on a QoQ basis from $337757.0 in Q4 2025, and up 67.76% year-over-year from -$19895.6 in Q1 2025.
Powered by 
Analysis
Trafalgar International (GCAN) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends
Trafalgar International has reported Net Income towards Common Stockholders for 10 years, with the latest figure at -$33376.0 in Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 67.76% year-over-year to -$33376.0 in Q1 2026; TTM through Mar 2026 was -$122571.0, a 48.49% increase from a year earlier, with the FY2025 full-year figure at -$331612.0, down 85.22% from the prior year.
- Net Income towards Common Stockholders was -$33376.0 for Q1 2026 at Trafalgar International, down from $337757.0 in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $337757.0 in Q4 2025, with the low at -$390853.0 in Q2 2025.
- Average Net Income towards Common Stockholders over 5 years is -$56105.5, with a median of -$46165.0 recorded in 2024.
- The largest YoY upside for Net Income towards Common Stockholders was 879.18% in 2025 against a maximum downside of 770.17% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$47401.0 in 2022, then advanced by 1.14% to -$46861.0 in 2023, then gained by 7.5% to -$43348.0 in 2024, then jumped by 879.18% to $337757.0 in 2025, then plunged by 109.88% to -$33376.0 in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$33376.0 (Q1 2026), $337757.0 (Q4 2025), and -$36099.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -238.00 Mn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 398.69 Mn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | -644.37 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 585.61 Mn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 333.00 Mn |
| 10 | Trafalgar International | 217,335.05 | 217,335.05 | - | -33,376.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -33,376.00 |
| Dec 31, 2025 | 337,757.00 |
| Sep 30, 2025 | -36,099.00 |
| Jun 30, 2025 | -390,853.00 |
| Mar 31, 2025 | -103,511.00 |
| Dec 31, 2024 | -43,348.00 |
| Sep 30, 2024 | -46,165.00 |
| Jun 30, 2024 | -44,917.00 |
| Mar 31, 2024 | -44,611.00 |
| Dec 31, 2023 | -46,861.00 |
| Sep 30, 2023 | -53,430.00 |
| Jun 30, 2023 | -45,043.00 |
| Mar 31, 2023 | -43,068.00 |
| Dec 31, 2022 | -47,401.00 |
| Sep 30, 2022 | -102,776.00 |
| Jun 30, 2022 | -62,405.00 |
| Mar 31, 2022 | -147,686.00 |
| Dec 31, 2021 | -196,331.00 |
| Sep 30, 2021 | -252,278.00 |
| Jun 30, 2021 | -38,964.00 |